Drugs / GOLNERMINOGENE PRADENOVEC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00496535 | — | head and neck cancer | GenVec | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00261404 | — | melanoma | GenVec | Completed | No outcome recorded |
| Phase 2 | NCT00137878 | — | rectal cancer | GenVec | Completed | No outcome recorded |
| Phase 2 | NCT00051480 | — | esophageal cancer | GenVec | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00051467 | — | malignant pancreatic neoplasm | GenVec | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GOLNERMINOGENE PRADENOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108704 ↗ |
| Known as | ADGV EGR.TNF.11D | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108704 ↗ |
| Known as | Golnerminogen pradenovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108704 ↗ |
| Known as | TNFerade | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00051467 ↗ |
| Known as | TNFerade Biologic | “TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells.” NCT00051467 ↗ |
| Route | Other | “TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).” NCT00051467 ↗ |
| Target | TNF | “containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter” NCT00051467 ↗ |